Latest From Alkermes PLC
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Label offers little differentiation from Tecfidera, but head-to-head trial with custom-designed patient-reported outcome could make case for gastrointestinal tolerability advantage.
- Large Molecule
- Nanotechnology, Chips, etc.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alkermes Inc.
- Western Europe
- Parent & Subsidiaries
- Alkermes PLC
- Senior Management
Richard F Pops, Chmn. & CEO
James M Frates, SVP, CFO
Michael J Landine, SVP, Corp. Dev.
Craig Hopkinson, MD, CMO & SVP, Medicines Dev. & Medical Affairs
Georgianna Harris, PhD, SVP, Reg. Affairs
- Contact Info
Phone: 1 772 8000
1 Burlington Rd.
Dublin 4, MA D04 C5Y6
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.